Advanced Accelerator Applications Molecular Imaging Iberica
Advanced Accelerator Applications Molecular Imaging Iberica is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) study
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with androgen receptor pathway inhibitors in patients with PSMA PET scan positive castration-resistant prostate cancer (PSMACare)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Treatment Phase.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Study protocol title: A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Advanced Accelerator Applications Molecular Imaging Iberica?
The 2026-10-09 snapshot links Advanced Accelerator Applications Molecular Imaging Iberica to 9 distinct CTIS trials. Recorded services include Medicinal product management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Advanced Accelerator Applications Molecular Imaging Iberica?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology. Recorded phases include Phase 1, Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Advanced Accelerator Applications Molecular Imaging Iberica conducted?
The linked trials record locations in 15 countries, including Germany, Spain, France, Netherlands, Italy. These are trial locations, not confirmed office locations or countries where Advanced Accelerator Applications Molecular Imaging Iberica delivered services.
What can this page tell me about Advanced Accelerator Applications Molecular Imaging Iberica's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Advanced Accelerator Applications Molecular Imaging Iberica. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Advanced Accelerator Applications Molecular Imaging Iberica S.L.